Moderna now projects 2025 revenue of approximately 1.9 billion, roughly 100 million above the midpoint of its previously communicated 1.6 billion to 2 billion range. This update reflects continued demand for its respiratory franchise, including seasonal influenza and combination flu-COVID vaccine candidates currently under regulatory review. Management also reiterated its expectation for revenue growth of up to 10% in 2026, underscoring confidence in sustained market uptake and pricing power as pandemic-era volumes normalize.

The company raised its 2025 GAAP operating expense outlook by 200 million, bringing the range to 5 billion to 5.2 billion. This adjustment primarily reflects expanded investments in late-stage clinical development and manufacturing scale-up for both respiratory and oncology programs. Moderna’s leadership emphasized that higher R&D and commercial spend will support anticipated clinical readouts and product launches in 2026, even as management targets improved operating leverage over the medium term.

Moderna forecasts a year-end cash balance of approximately 8.1 billion, which includes a 600 million drawdown from a recently announced 1.5 billion term loan facility. The company highlighted that its robust cash reserves and access to committed debt capacity provide flexibility to fund pipeline expansion, strategic partnerships and potential bolt-on acquisitions without reliance on equity raises in the near term.

Moderna reports three FDA-approved products on the market and two respiratory vaccine candidates—seasonal flu and combination flu-COVID—submitted for regulatory approval. Its norovirus vaccine program is currently in Phase III, with data anticipated in late 2025. In oncology, the company detailed a diversified mRNA portfolio targeting multiple tumor types, with key clinical catalysts slated throughout 2026. Management stressed that success in these programs would further diversify revenue streams beyond its core respiratory franchise.